Home > Boards > US Listed > Biotechs > Evoke Pharma Inc. (EVOK)

positive results $11.35

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
Quarterly Report (10-q) Edgar (US Regulatory) - 11/10/2020 8:31:21 AM
Evoke Pharma Reports Third Quarter 2020 Financial Results GlobeNewswire Inc. - 11/10/2020 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/10/2020 8:29:03 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/26/2020 8:36:29 AM
Evoke and EVERSANA Announce Commercial Launch of Gimoti™ GlobeNewswire Inc. - 10/26/2020 8:30:10 AM
Evoke Pharma to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire Inc. - 9/9/2020 8:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/2/2020 4:15:51 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2020 8:31:04 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2020 8:30:59 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/2/2020 8:30:51 AM
Evoke Pharma and EVERSANA Announce the Appointment of Christopher Quesenberry as Chief Commercial Officer for Gimoti™ GlobeNewswire Inc. - 8/25/2020 8:30:10 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2020 8:37:08 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:31:01 AM
Evoke Pharma Reports Second Quarter 2020 Financial Results GlobeNewswire Inc. - 8/6/2020 8:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/15/2020 8:36:20 AM
Evoke Pharma Initiates Commercial Manufacturing of Gimoti™ GlobeNewswire Inc. - 7/15/2020 8:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 8:41:25 AM
Evoke Pharma Extends Cash Runway to 2Q 2021 GlobeNewswire Inc. - 7/8/2020 8:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 3:40:18 PM
FDA Approves Evoke’s GIMOTI™ GlobeNewswire Inc. - 6/19/2020 3:32:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 5:07:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 4:51:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 4:50:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 4:46:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2020 4:44:09 PM
mlkrborn   Wednesday, 01/22/14 01:24:06 PM
Re: None
Post # of 1645 
positive results $11.35
Evoke Pharma study reports positive results of Metoclopramide nasal spray for Gastroparesis in Diabetics (EVOK) : Co announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing symptoms of diabetic gastroparesis compared to the marketed oral tablet formulation of metoclopramide. The Phase 2b study, which was published online ahead-of-print for an upcoming issue of Neurogastroenterology & Motility, enrolled 89 patients from six study sites throughout the United States. The multicenter, randomized, open-label, parallel design study was the first to compare the efficacy and safety of metoclopramide nasal spray to oral tablets in diabetic patients with symptoms of gastroparesis when dosed four times a day for 6 weeks.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences